Liquidia Technologies (NASDAQ:LQDA) had its target price raised by Wedbush from $47.00 to $48.00 in a report published on Tuesday morning. Wedbush currently has an outperform rating on the stock.

Separately, Zacks Investment Research raised Liquidia Technologies from a sell rating to a hold rating in a report on Friday, January 4th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Liquidia Technologies has an average rating of Buy and a consensus target price of $36.75.

Shares of NASDAQ LQDA opened at $16.65 on Tuesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.85 and a quick ratio of 4.85. Liquidia Technologies has a 1-year low of $10.52 and a 1-year high of $38.46. The firm has a market cap of $259.14 million and a P/E ratio of -2.22.

Liquidia Technologies (NASDAQ:LQDA) last issued its quarterly earnings results on Tuesday, February 26th. The company reported ($0.62) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.08. On average, sell-side analysts predict that Liquidia Technologies will post -2.22 earnings per share for the current fiscal year.

In other Liquidia Technologies news, SVP Benjamin Maynor sold 2,187 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $19.84, for a total value of $43,390.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin K. Gordon sold 11,322 shares of the firm’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $14.66, for a total value of $165,980.52. The disclosure for this sale can be found here. In the last three months, insiders sold 14,452 shares of company stock valued at $225,496.

A number of institutional investors have recently added to or reduced their stakes in LQDA. New York State Common Retirement Fund acquired a new stake in Liquidia Technologies in the fourth quarter valued at $96,000. TIAA CREF Investment Management LLC acquired a new stake in Liquidia Technologies in the third quarter valued at $336,000. Bank of New York Mellon Corp acquired a new stake in Liquidia Technologies in the fourth quarter valued at $403,000. Laurion Capital Management LP acquired a new stake in Liquidia Technologies in the third quarter valued at $480,000. Finally, Geode Capital Management LLC lifted its holdings in Liquidia Technologies by 50.1% in the fourth quarter. Geode Capital Management LLC now owns 49,319 shares of the company’s stock valued at $1,068,000 after acquiring an additional 16,453 shares during the period. 47.32% of the stock is owned by institutional investors.

About Liquidia Technologies

Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.

See Also: Why is the price-sales ratio important?

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.